Please assess the completion status of the following clinical trial:

Trial Title: 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating female patients~* Diagnosis of moderate to severe AS with prior documented radiologic evidence (x-ray) fulfilling the Modified New York criteria for AS (1984)~* Patients should have been on NSAIDs with an inadequate response~* Patients who were regularly taking NSAIDs as part of their AS therapy are required to be on a stable dose~* Patients who had been on an anti-TNFα agent (not more than one) must have experienced an inadequate response~Exclusion Criteria:~* Chest X-ray (or MRI) with evidence of ongoing infectious or malignant process~* Patients with total ankylosis of the spine~* Patients previously treated with any biological immunomodulating agents except for those targeting TNFα~* Previous treatment with any cell-depleting therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 75 mg (Type: EXPERIMENTAL): Secukinumab 75 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks.
- Secukinumab 150 mg (Type: EXPERIMENTAL): Secukinumab 150 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).